trending Market Intelligence /marketintelligence/en/news-insights/trending/53LtkCcUowW0n59TNYf-Xg2 content esgSubNav
In This List

Mylan gets US FDA approval for 1st generic of Allergan's Estrace Cream

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Mylan gets US FDA approval for 1st generic of Allergan's Estrace Cream

Mylan NV launched its Estradiol vaginal cream 0.01% in the U.S. after final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for the product to treat vulvar and vaginal atrophy.

Estradiol vaginal cream 0.01% is the first generic version of Allergan plc's Estrace Cream.

Estradiol vaginal cream 0.01% had U.S. sales of about $449 million for the 12 months ending Oct. 31, according to IQVIA.